radiotherapy

Gimeracil (Gimestat) 是一种竞争性可逆的 DPYD(二氢嘧啶脱氢酶，DPD) 有效抑制剂，是口服氟嘧啶衍生物 S-1 的成分，能够抑制 DNA DSB 的修复。

CT-179是一种高效和选择性的少突胶质细胞转录因子2（OLIG2）抑制剂，减少肿瘤细胞增殖和诱导细胞凋亡，并与放疗和其他药物联合使用时增强疗效，在治疗髓母细胞瘤和胶质母细胞瘤中显示出潜力。

3M-011, a potent dual toll-like receptor TLR7 8 agonist and cytokine inducer, serves as a powerful adjuvant to radiotherapy, eliciting significant local and systemic immune responses. Additionally, it effectively inhibits H3N2 influenza viral replication in the nasal cavity and exhibits strong antitumor activity[1][2][3].

BSc5367是Nek1激酶结构域的有效抑制剂，IC50=11.5 nM。Nek1 是一种NIMA 相关的蛋白激酶，与细胞周期调节、DNA 修复和微管调节紧密相关。BSc5367可用于肌萎缩侧索硬化症 (ALS)、多囊肾病 (PKD) 和几种类型的放疗耐药性癌症的相关研究。

Cevimeline, a parasympathomimetic and muscarinic agonist, affects M1 and M3 receptors. Cevimeline has been shown to treat dry mouth and Sj gren's syndrome. It is also used to reduce Xerostomia symptoms and increase salivary flow in head and neck cancer survivors after radiotherapy.

NIMUSTINE, an antineoplastic agent especially effective against malignant brain tumors, has been used in combination with other antineoplastic agents or with radiotherapy for the treatment of various neoplasms.

Bimiralisib (PI3K-IN-2) 是一种有效的，可渗透脑的 mTOR PI3K 抑制剂，是一种 mTORC1和 mTORC2抑制剂。它能够抑制 PI3Kα,PI3Kδ,PI3Kβ,PI3Kγ和 mTOR，IC50分别为 33 nM，451 nM，661 nM，708 nM 和 89 nM。

Dolasetron Mesylate hydrate (Dalasetron Mesylate Hydrate) 是一种选择性血清素受体拮抗剂，可竞争性阻断血清素对 5HT3 受体的作用，从而抑制化疗和放疗引起的恶心和呕吐。

BMS-599626 2HCL (AC480 2HCl) 是BMS-599626 衍生物。BMS-599626 是一种可口服且具有选择性的 HER1 和 HER2 双重抑制剂， IC50 分别为 20 和 30 nM。BMS-599626 抑制肿瘤细胞增殖，并有可能增加肿瘤对放疗的反应。

CMP3a is a NEK2 kinase inhibitor. CMP3a efficiently attenuated GBM growth in a mouse model and exhibited a synergistic effect with radiotherapy. Targeting NEK2 attenuates glioblastoma growth and radioresistance by destabilizing histone methyltransferase E

L-778123 is an inhibitor of FPTase and GGPTase-I. The combination of L-778123 and radiotherapy at dose level 1 showed acceptable toxicity in patients with locally advanced pancreatic cancer.

GLYN, a nitric oxide donor, acts by enhancing the therapeutic efficacy of chemotherapy and radiotherapy.

NLCQ-1 is a novel weak DNA-intercalative bioreductive compound. NLCQ-1 exhibited a C50 of 44 microM. NLCQ-1 demonstrated significant hypoxic selectivity in several rodent (V79, EMT6, SCCVII) or human (A549, OVCAR-3) tumor cell lines. Its potency as a hypo

β,β-Dimethylacrylshikonin (Dimethylacrylshikonin) 是一种萘醌衍生物，从 Arnebia nobilis 中提取得到。它利用 PI3K 通路诱导 eNOS、VEGF 和 HIF-1α 的表达，促进血管生成，具有抗肿瘤活性。

DNA-PK-IN-6, a robust DNA-PK inhibitor, effectively hampers the activity of DNA-PKcs, thereby significantly impairing the DNA repair mechanism in tumors and instigating apoptosis in cells. Additionally, DNA-PK-IN-6 amplifies the responsiveness of tumor tissues to radiotherapy, overcomes the challenge of drug resistance, and augments its inhibitory impact on a diverse range of solid and hematological tumors[1].

DNA-PK-IN-3 is a highly potent inhibitor of DNA-PK. This compound exerts a synergistic effect when combined with radiotherapy and chemotherapy, resulting in enhanced therapeutic outcomes and significant inhibition of tumor growth. Furthermore, DNA-PK-IN-3 demonstrates remarkable efficacy in reducing damage to normal cells, effectively minimizing adverse side effects. Due to these compelling properties, DNA-PK-IN-3 holds great potential for cancer research applications[1].

DNA-PK-IN-5 是一种 DNA-PK 的有效抑制剂。DNA-PK-IN-5 能够抑制 DNA-PKcs 活性，明显降低肿瘤 DNA 修复，并诱导细胞凋亡。DNA-PK-IN-5 能够提高肿瘤组织对放疗的敏感性，克服耐药问题，提高对多种实体瘤和血液肿瘤的抑制效果。

GPI-15427 is a potent PARP-1 inhibitor capable of crossing the blood-brain barrier, which can significantly increased the antitumor activity of the methylating agent TMZ against malignant melanoma, glioblastoma multiforme, or lymphoma growing at the CNS site. GPI-15427 acts as a potent inhibitor of the enzyme, being capable of inhibiting the activity of purified PARP-1 at nanomolar concentrations. GPI-15427 induced significant sensitization to radiotherapy, representing a promising new treatment in the management of HNSCC.

EPZ020411 is a potent and selective PRMT6 inhibitor tool compound. EPZ020411 shows good bioavailability following subcutaneous dosing in rats making it a suitable tool for in vivo studies. EPZ020411 suppresses RCC1 arginine methylation and improves the cytotoxic activity of radiotherapy against GSC brain tumor xenografts.

L-778123 is an inhibitor of FPTase and GGPTase-I, which was developed in part because it can completely inhibit Ki-Ras prenylation. The combination of L-778,123 and radiotherapy at dose level 1 showed acceptable toxicity in patients with locally advanced pancreatic cancer. Radiosensitization of a patient-derived pancreatic cancer cell line was observed.

DC-Y13-27 是一种 DC-Y13 的衍生物，是一种有效的 YTHDF2 抑制剂 (KD: 37.9 μM)。DC-Y13-27 具有抗肿瘤活性，可增强放疗和免疫疗法对肿瘤的响应。

Polysaccharidase (Tremella polysaccharide) 是一种提升免疫功能的真菌多糖。该化合物展现出治疗化疗和放疗导致的白细胞减少症的研究潜力。

EB-PSMA-617是PSMA-617的改进版本，通过与埃文斯蓝 (EB) 的结合，旨在延长药物的循环半衰期并优化药代动力学特性，进而提升其在前列腺肿瘤中的摄取率和放射疗效。在对PC3-PIP负荷的小鼠进行的临床前试验中，EB-PSMA-617不仅显著延长了在血液中的半衰期，也增加了对PSMA阳性肿瘤的积累，并通过较少的放射性剂量成功地消除了肿瘤。

Protohypericin 是一种从贯叶连翘中提取的天然石脑粉。放射性碘化 Protohypericin 能用于肿瘤坏死靶向放射研究。